Human IGF-I R / CD221 Protein, His Tag (MALS verified)
分子别名（Synonym）
IGF1R,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216
表达区间及表达系统（Source）
Human IGF-I R, His Tag (IGR-H5229) is expressed from human 293 cells (HEK293). It contains AA Glu 31 - Asn 932 (Accession # P08069-1).
Predicted N-terminus: Glu 31
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
This protein contains a furin convertase cleavage site, 737-RKRR-740, and will be partially processed into N (α chain) and C-terminal fragment (partial β chain) with calculated MW of 81.0 kDa and 23.8 kDa respectively. The protein migrates as 35-45 kDa (partial β chain), 110-120 kDa (α chain) and 130 kDa (α chain & partial β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
胰岛素样生长因子1受体（IGF1R）又称CD221、JTK13，是一种可被IGF-1及相关生长因子IGF-2激活的跨膜受体，属于酪氨酸激酶受体大类。该受体介导IGF-1的生物学效应——IGF-1是一种多肽类蛋白激素，其分子结构与胰岛素相似。IGF1R由两个α亚基和两个β亚基构成，二者均源自同一mRNA前体。该前体经糖基化修饰、蛋白酶水解及二硫键交联后，形成具有功能的跨膜αβ链：α链定位在细胞膜外侧，β链则跨膜分布并在配体刺激下负责胞内信号转导。IGF1R具有ATP结合位点，为自身磷酸化过程提供磷酸基团。该受体与胰岛素受体存在60%的同源性。配体结合后，α链诱导β链发生酪氨酸自身磷酸化，进而触发胞内信号级联反应。此过程虽具细胞类型特异性，但通常促进细胞存活与增殖。
关键字： IGF-I R;IGF-I R蛋白;IGF-I R重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。